Assertio Therapeutics Inc (ASRT) Stock Price, Quote & News

Company Profile

Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut sy...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 224 419 7106

Fax: 510 744 8001

Website: www.assertiotx.com

Address:

100 South Saunders Road, Suite 300, Lake Forest, United States

Whytheykeepmutingme Oct. 24 at 9:32 PM

$NOMD $TKC $ASRT $TV $PXS

0 · Reply

25_usa Oct. 24 at 3:22 PM

$ASRT Brandon? What’s he even doing here? It’s disgraceful — he should be fired as soon as this season ends

1 · Reply

Invest2live Oct. 22 at 8:54 PM

$ASRT $IBIO $REKR $IBIO 80% in a few days; congrats 🎈 🌿🎉 Checkout $RXRX and $CLYM

0 · Reply

IBUYSELLHOLD Oct. 21 at 3:21 PM

$ASRT / yep, I'll invest after the split

0 · Reply

25_usa Oct. 21 at 1:50 PM

$ASRT Rolvedon and Sympazan are the primary contributors to the company’s revenue. The company could likely sold by at least $700 million from these assets, in addition to other assets. Brandon should take an active role in the next phase to ensure that the deal is completed before the end of the year. If he is unable to do so, he should consider stepping down from the board. Two years have been sufficient to demonstrate his leadership and capabilities with this team, and his evaluation period concludes this year.

2 · Reply

Avedisian Oct. 20 at 9:04 PM

$ASRT This is a old claim which was paid from insurance in May qtr, this is asking for people to submit proof and get claims

2 · Reply

11thestate Oct. 20 at 2:48 PM

$ASRT has reached a $15.95M settlement with $ASRT investors over claims that it misled them about the effectiveness and FDA approval prospects of its two lead drug candidates. The filing deadline is October 1, 2025. If you bought $ASRT between March 7, 2018, and August 5, 2021, you can file for payment here: https://11th.com/cases/spectrum-investor-settlement?utm_source=stocktwits&utm_medium=referral&utm_campaign=ddl&utm_content=10202025_1

2 · Reply

EMINENZ Oct. 20 at 1:18 PM

$ASRT sell the company brendan!

0 · Reply

CliffordCapital Oct. 18 at 7:34 AM

$ASRT nothing to see here. Just algos trading back and forth. Need the next ER to be great and a Brendon to give a good outlook on the company .. then we can surpass 1$ finally.

0 · Reply

Chuckuk Oct. 16 at 1:43 PM

$ASRT Scrips for Rolvedon anyone?

0 · Reply

DEADLINE NEXT WEEK: Berger Montague Advises Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) Investors to Contact the Firm Before September 24, 2025

Sep 15, 2025, 9:00 AM EDT - 5 weeks ago

Assertio Presents First-Ever Real-World Study Showing Patient Experience with SYMPAZAN® (clobazam) Oral Film, CIV

Sep 10, 2025, 7:30 AM EDT - 6 weeks ago

Assertio to Present New Data from Real-World Evidence Study of SYMPAZAN® at upcoming 150th Annual Meeting of the American Neurological Association

Sep 3, 2025, 8:15 AM EDT - 7 weeks ago

Assertio to Participate in the HC Wainwright and Lake Street Conferences in September 2025

Aug 11, 2025, 7:41 PM EDT - 2 months ago

Assertio Holdings, Inc. (ASRT) Q2 2025 Earnings Call Transcript

Aug 11, 2025, 4:05 PM EDT - 2 months ago

Assertio Reports Second Quarter 2025 Financial Results

Aug 6, 2025, 3:41 PM EDT - 2 months ago

Berger Montague PC Investigating Claims on Behalf of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) Investors

Aug 5, 2025, 8:30 AM EDT - 2 months ago

Assertio Holdings, Inc. to Report Second Quarter 2025 Financial Results on August 11, 2025

May 19, 2025, 4:10 PM EDT - 5 months ago

Assertio to Participate in the Alliance Global Partners Healthcare Company Showcase on May 21, 2025

May 12, 2025, 8:17 PM EDT - 5 months ago

Assertio Holdings, Inc. (ASRT) Q1 2025 Earnings Call Transcript

May 12, 2025, 4:01 PM EDT - 5 months ago

Assertio Reports First Quarter 2025 Financial Results

May 5, 2025, 8:15 AM EDT - 6 months ago

Assertio Holdings, Inc. to Report First Quarter 2025 Financial Results on May 12, 2025

Mar 20, 2025, 9:10 AM EDT - 7 months ago

Assertio to Participate in the iAccess Alpha Virtual Best Ideas Conference on March 25-26, 2025

Mar 12, 2025, 6:53 PM EDT - 8 months ago

Assertio Holdings, Inc. (ASRT) Q4 2024 Earnings Call Transcript

Mar 12, 2025, 4:05 PM EDT - 8 months ago

Assertio Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 5, 2025, 4:05 PM EST - 8 months ago

Assertio Holdings, Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 12, 2025

Jan 3, 2025, 4:30 PM EST - 10 months ago

Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Dec 17, 2024, 8:30 AM EST - 11 months ago

Assertio Holdings, Inc. Appoints Mark Reisenauer to Its Board of Directors

Dec 13, 2024, 8:00 AM EST - 11 months ago

Assertio Announces Results of Rolvedon® (eflapegrastim-xnst) injection Same-Day Dosing Clinical Study

Nov 15, 2024, 9:00 AM EST - 1 year ago

Buxton Helmsley Calls for Senate Hearing on Well-Documented Evident Clinical Data Fraud at Assertio

Nov 11, 2024, 6:57 PM EST - 1 year ago

Assertio Holdings, Inc. (ASRT) Q3 2024 Earnings Call Transcript

Nov 11, 2024, 4:02 PM EST - 1 year ago

Assertio Reports Third Quarter 2024 Financial Results

Nov 11, 2024, 3:41 PM EST - 1 year ago

Buxton Helmsley Releases Evidence of Product-Related Fraud at Assertio

Nov 11, 2024, 7:30 AM EST - 1 year ago

Assertio Provides Response to Letter from Short-seller

Nov 8, 2024, 9:00 AM EST - 1 year ago

Buxton Helmsley Issues Letter to Assertio Stockholders Disclosing Inversion to Short Position Following Board Refusal to Address Product-Related Fraud

Oct 11, 2024, 8:00 AM EDT - 1 year ago

Assertio to Participate in the Maxim Group Healthcare Virtual Summit on October 15, 2024

Sep 11, 2024, 4:18 PM EDT - 1 year ago

Assertio Holdings: Management Change Could Improve Comeback Chances

Sep 3, 2024, 4:05 PM EDT - 1 year ago

Assertio to Participate in the HC Wainwright and Lake Street Conferences in New York City September 10-12, 2024

Aug 7, 2024, 9:45 PM EDT - 1 year ago

Assertio Holdings, Inc. (ASRT) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 4:01 PM EDT - 1 year ago

Assertio Reports Second Quarter 2024 Financial Results

Jul 24, 2024, 4:05 PM EDT - 1 year ago

Assertio Holdings, Inc. to Report Second Quarter 2024 Financial Results on August 7, 2024

Jul 24, 2024, 9:00 AM EDT - 1 year ago

Buxton Helmsley Issues Letter to the Board of Directors of Assertio Holdings, Inc.

Jun 27, 2024, 9:51 AM EDT - 1 year ago

Assertio: An Extremely Asymmetric Bet Skewed To The Upside

Jun 5, 2024, 8:30 AM EDT - 1 year ago

Assertio to Participate in the Sidoti Small Cap Conference on June 12, 2024

May 17, 2024, 9:15 AM EDT - 1 year ago

Assertio to Participate in Benchmark Healthcare Conference on May 21-22

May 17, 2024, 7:30 AM EDT - 1 year ago

BUXTON HELMSLEY RELEASES LETTER FROM CERTIFIED FRAUD EXAMINER ATTESTING TO DISCLOSURE FAILURES AND DEFICIENCIES BY ASSERTIO HOLDINGS BOARD OF DIRECTORS

May 16, 2024, 9:16 AM EDT - 1 year ago

Assertio to Participate in AGP Healthcare Conference on May 21

May 13, 2024, 5:52 PM EDT - 1 year ago

BUXTON HELMSLEY URGES ASSERTIO STOCKHOLDERS TO VOTE "AGAINST" DIRECTORS AFTER DISCLOSURE FAILURES, INAPPROPRIATE BOARDROOM ACTIVITY, STRATEGIC BLUNDERS

May 10, 2024, 3:12 PM EDT - 1 year ago

Assertio to Present at the Citizens JMP Life Sciences Conference in New York City

May 6, 2024, 7:07 PM EDT - 1 year ago

Assertio Holdings, Inc. (ASRT) Q1 2024 Earnings Call Transcript

May 6, 2024, 4:01 PM EDT - 1 year ago

Assertio Reports First Quarter 2024 Financial Results

Apr 25, 2024, 8:00 AM EDT - 1 year ago

Assertio Holdings, Inc. to Report First Quarter 2024 Financial Results on May 6, 2024

Apr 1, 2024, 9:00 AM EDT - 1 year ago

Assertio to Present at LD Micro Invitational Conference in New York City

Mar 11, 2024, 6:02 PM EDT - 1 year ago

Assertio Holdings Inc. (ASRT) Q4 2023 Earnings Call Transcript

Mar 11, 2024, 4:01 PM EDT - 1 year ago

Assertio Reports Fourth Quarter and Full Year 2023 Financial Results

Whytheykeepmutingme Oct. 24 at 9:32 PM

$NOMD $TKC $ASRT $TV $PXS

0 · Reply

25_usa Oct. 24 at 3:22 PM

$ASRT Brandon? What’s he even doing here? It’s disgraceful — he should be fired as soon as this season ends

1 · Reply

Invest2live Oct. 22 at 8:54 PM

$ASRT $IBIO $REKR $IBIO 80% in a few days; congrats 🎈 🌿🎉 Checkout $RXRX and $CLYM

0 · Reply

IBUYSELLHOLD Oct. 21 at 3:21 PM

$ASRT / yep, I'll invest after the split

0 · Reply

25_usa Oct. 21 at 1:50 PM

2 · Reply

Avedisian Oct. 20 at 9:04 PM

$ASRT This is a old claim which was paid from insurance in May qtr, this is asking for people to submit proof and get claims

2 · Reply

11thestate Oct. 20 at 2:48 PM

2 · Reply

EMINENZ Oct. 20 at 1:18 PM

$ASRT sell the company brendan!

0 · Reply

CliffordCapital Oct. 18 at 7:34 AM

$ASRT nothing to see here. Just algos trading back and forth. Need the next ER to be great and a Brendon to give a good outlook on the company .. then we can surpass 1$ finally.

0 · Reply

Chuckuk Oct. 16 at 1:43 PM

$ASRT Scrips for Rolvedon anyone?

0 · Reply

Invest2live Oct. 15 at 7:29 PM

$REKR 106% already; congrats 🎈🎊🎉🌿 Checkout $IBIO and $ASRT; do your DD and get in.

0 · Reply

Chuckuk Oct. 15 at 7:20 PM

$ASRT So just saying Udencya sold for $558 it treats like Rolvedon but doesn't have any same day prospects so what's it worth???? It is just a bit different in formulation as well.

1 · Reply

Blue_mist Oct. 15 at 7:19 AM

$ASRT when are we going back to $8 again ?

0 · Reply

Invest2live Oct. 14 at 2:28 PM

$REKR 85% already; congrats 🎉 🎊🎈 Checkout $ASRT and $MBIO

0 · Reply

Luckybreak Oct. 14 at 3:49 AM

$ASRT Rolvedon is not biosimilar like Udenyca which was recently sold by CHRS

2 · Reply

Avedisian Oct. 13 at 9:39 PM

$ASRT New research on same day for Neulasta, Udenyca and the other biosimilars. In summary it just can't be given, you have to go for Rolvedon if you want same day https://spcare.bmj.com/content/15/5/543

1 · Reply

caddaly Oct. 13 at 3:13 PM

$ASRT I would really like to see this seller get finished and then a rally into earnings.

1 · Reply

Luckybreak Oct. 13 at 1:39 PM

$ASRT Anyone any idea why this has market cap of $77 million and dropping when it makes so much money and has so much cash in hand compared to it’s market cap

1 · Reply

Avedisian Oct. 12 at 2:12 PM

$ASRT It could be that they see good sales volume coming up for Rolvedon that they negotiated a lower cost ... can't think of a reason why they would lower price.

0 · Reply

Lassekat Oct. 11 at 5:59 AM

$ASRT

0 · Reply

Ulixes1991 Oct. 10 at 10:25 PM

$ASRT good news, right? Lower COGS: https://d18rn0p25nwr6d.cloudfront.net/CIK-0001808665/b5d47d0f-db38-451b-af2f-3822f32be143.pdf

0 · Reply

Chuckuk Oct. 10 at 6:19 PM

$ASRT any luck with the Scrip figures

0 · Reply

Market Cap	78.92M
Revenue (ttm)	124.96M
Net Income (ttm)	-21.58M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-17.27%
Debt to Equity Ratio	0.42

Volume	79,400
Avg Vol	242,480
Day's Range	N/A - N/A
Shares Out	96.24M
Stochastic %K	26%
Beta	0.28
Analysts	Strong Sell
Price Target	$2.75